LIDOCAINE CAS 137-58-6

Short Description:

Chemical & Physical Properties Common Name Lidocaine CAS Number 137-58-6 Purity 99% Molecular Weight 234.337 Density 1.0±0.1 g/cm3 Boiling Point 372.7±52.0 °C at 760 mmHg Molecular Formula C14H22N2O Melting Point 66-69°C Flash Point 179.2±30.7 °C Packing 1kg/Aluminum foil bag, inner double plastic bags 25kg/Fiber drum, inner double plastic bags Shipping way 1. Ship by DHL/ FedEx/ UPS/EMS 2. Ship by special line if you can not make clearance when goods reach your customs 3. Ship by air/ se…

FOB Price: US $0.5 - 9,999 / Piece

Min.Order Quantity: 100 Piece/Pieces

Supply Ability: 10000 Piece/Pieces per Month

Send email to us

Product Detail

Product Tags

Chemical & Physical Properties

Common Name Lidocaine

CAS Number 137-58-6

Purity 99%

Molecular Weight 234.337

Density 1.0±0.1 g/cm3

Boiling Point 372.7±52.0 °C at 760 mmHg

Molecular Formula C14H22N2O

Melting Point 66-69°C

Flash Point 179.2±30.7 °C

Packing
1kg/Aluminum foil bag, inner double plastic bags

25kg/Fiber drum, inner double plastic bags

Shipping way

1. Ship by DHL/ FedEx/ UPS/EMS
2. Ship by special line if you can not make clearance when goods reach your customs
3. Ship by air/ sea

Use of Lidocaine

Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to an attenuation of pro-inflammatory cytokines, intracellular adhesion molecule-1 (ICAM-1), and reduction of neutrophils influx.Target: Lidocaine is a common local anesthetic and antiarrhythmic drug. Lidocaine is used topically to relieve itching, burning and pain from skin inflammations, injected as a dental anesthetic or as a local anesthetic for minor surgery. Lidocaine, the first amino amide–type local anesthetic, was first synthesized under the name xylocaine by Swedish chemist Nils Lofgren in 1943. His colleague Bengt Lundqvist performed the first injection anesthesia experiments on himself.Lidocaine is approximately 95% metabolized (dealkylated) in the liver by CYP3A4 to the pharmacologically-active metabolites monoethylglycinexylidide (MEGX) and then subsequently to the inactive glycine xylidide. MEGX has a longer half life than lidocaine but also is a less potent sodium channel blocker. The elimination half-life of lidocaine is approximately 90–120 minutes in most patients. This may be prolonged in patients with hepatic impairment (average 343 minutes) or congestive heart failure (average 136 minutes).